Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2021 | CD73 Is regulated by the EGFR-ERK signaling pathway in non-small cell lung cancer | Griesing S.; BIN-CHI LIAO ; CHIH-HSIN YANG | Anticancer Research | 16 | 15 | |
2023 | Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma | Lim, Darren Wan-Teck; HSIANG-FONG KAO ; Suteja, Lisda; Li, Constance H; Quah, Hong Sheng; Tan, Daniel Shao-Weng; Tan, Sze-Huey; Tan, Eng-Huat; Tan, Wan-Ling; Lee, Justina Nadia; Wee, Felicia Yu-Ting; Jain, Amit; Goh, Boon-Cher; Chua, Melvin L K; BIN-CHI LIAO ; Ng, Quan Sing; RUEY-LONG HONG ; Ang, Mei-Kim; Yeong, Joe Poh-Sheng; Iyer, N Gopalakrishna | Nature communications | 6 | 1 | |
2015 | Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma | BIN-CHI LIAO ; YU-YUN SHAO ; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN ; Kuo R.N.; Lai C.-L.; KUO-HSING CHEN ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Clinical Lung Cancer | 11 | 8 | |
2017 | Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis | JHE-CYUAN GUO ; CHIN-CHEN CHANG ; Yang C.-Y.; BIN-CHI LIAO ; JAU-YU LIAU ; Chang C.-H.; KUN-HUEI YEH | Medical Oncology | 5 | 3 | |
2016 | Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice | YI-HSIN LIANG ; YU-YUN SHAO ; BIN-CHI LIAO ; Lee, Ho-Sheng; CHIH-HSIN YANG ; Chen, Ho-Min; CHUN-JU CHIANG ; ANN-LII CHENG ; Lai, Mei-Shu | Journal of Cancer | 8 | 7 | |
2023 | Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors | DE-RUI HUANG ; BIN-CHI LIAO ; Hsu, Wei-Hsun; CHING-YAO YANG ; YEN-TING LIN ; SHANG-GIN WU ; TZU-HSIU TSAI ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG ; ANN-LII CHENG ; YING-CHUN SHEN | Oncology | | | |
2015 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis | BIN-CHI LIAO ; JIH-HSIANG LEE ; CHIA-CHI LIN ; YA-FANG CHEN ; Chang C.-H.; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 141 | 113 | |
2020 | Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer | Hsu C.-C.; BIN-CHI LIAO ; WEI-YU LIAO ; Markovets A.; Stetson D.; Thress K.; CHIH-HSIN YANG | Journal of Thoracic Oncology | 57 | 44 | |
2013 | First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Drugs | 16 | 16 | |
2012 | Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study | BIN-CHI LIAO ; CHIH-HSIN YANG | Translational Lung Cancer Research | 0 | 0 | |
2021 | Lung Cancer in Republic of China | Luo Y.-H.; Chiu C.-H.; Scott Kuo C.-H.; Chou T.-Y.; Yeh Y.-C.; Hsu H.-S.; Yen S.-H.; Wu Y.-H.; CHIH-HSIN YANG ; BIN-CHI LIAO ; Hsia T.-C.; Chen Y.-M. | Journal of Thoracic Oncology | 33 | 26 | |
2017 | Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Current Oncology Reports | 19 | 19 | |
2017 | Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy | BIN-CHI LIAO ; Chia-Chi Lin ; JIH-HSIANG LEE ; CHIH-HSIN YANG | Lung Cancer | 38 | 35 | |
2018 | Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors | BIN-CHI LIAO ; Bai Y.-Y; JIH-HSIANG LEE ; CHIA-CHI LIN ; SHU-YUNG LIN ; YEE-FAN LEE ; CHAO-CHI HO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG | Journal of the Formosan Medical Association | 11 | 9 | |
2023 | A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study) | Ang, Yvonne L E; Zhao, Xiaotian; Reungwetwattana, Thanyanan; Cho, Byoung-Chul; BIN-CHI LIAO ; Yeung, Rebecca; Loong, Herbert H; Kim, Dong-Wan; CHIH-HSIN YANG ; Lim, Sun Min; Ahn, Myung-Ju; Lee, Se-Hoon; Suwatanapongched, Thitiporn; Kongchauy, Kanchaporn; Ou, Qiuxiang; Yu, Ruoying; Tai, Bee Choo; Goh, Boon Cher; Mok, Tony S K; Soo, Ross A | Cancers | 2 | 0 | |
2015 | Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Current Opinion in Oncology | 122 | 109 | |
2019 | Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients | BIN-CHI LIAO ; Griesing S.; CHIH-HSIN YANG | Therapeutic Advances in Medical Oncology | 27 | 25 | |
2021 | Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC | BIN-CHI LIAO ; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHING-YAO YANG ; TZU-HSIU TSAI ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; Soo, Ross A; CHIH-HSIN YANG | JTO clinical and research reports | 2 | 0 | |
2022 | Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis | HSIANG-FONG KAO ; HUAI-CHENG HUANG ; BIN-CHI LIAO ; RUEY-LONG HONG | BMC cancer | 3 | 2 | |
2018 | Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Expert Opinion on Pharmacotherapy | 5 | 5 | |